Significance of Clinical-Pathological Correlation in Ponatinib Reactions
Keywords:
Ponatinib, Adverse Drug Reactions, Stevens-Johnson SyndromeReferences
Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482-3. DOI: 10.1159/000351918. PMID: 23969404.
Massaro F, Molica M, Breccia M. Ponatinib: A Review of Efficacy and Safety. Curr Cancer Drug Targets. 2018;18(9):847-56. DOI: 10.2174/1568009617666171002142659. PMID: 28969556.
Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117(3):620-22. DOI:10.1046/j.1365-2141.2002.03499.x. PMID: 12028031.
Chaigne B, Lagier L, Aubourg A, et al. Stevens-Johnson Syndrome induced by masitinib. Acta Derm Venereol. 2012;92(2):210-2. DOI: 10.2340/00015555-1196. PMID: 21953477.
Danish M, Patel V, Arava S, Ahuja R. Ponatinib-induced desquamation-Unifying eponymous terminology for a rare adverse event. J Eur Acad Dermatol Venereol. 2024;38(3):e247-e249. DOI:10.1111/jdv.19553 Danish M, Patel V, Arava S, Ahuja R. Ponatinib-induced desquamation-Unifying eponymous terminology for a rare adverse event. J Eur Acad Dermatol Venereol. 2024;38(3):e247-e249. DOI: 10.1111/jdv.19553. PMID: 37795667.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Judith Monserrat Corona Herrera, Fanny Carolina López Jiménez, Verónica Monserrat Díaz Sánchez , Betzabé Quiles Martínez , Marcela Saeb Lima, Silvia Méndez Flores

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.